Qiming Venture Partners | Global Top Biotech VCs Gather, First S2S China Symposium Startup Proposal Countdown Begins
Top scientists are invited to visit the S2SChina website and submit proposals, embarking on an accelerated journey from the lab to entrepreneurship.
The inaugural S2S (Science2Startup) China Symposium, co-hosted by leading global venture capital firms RA Capital Management and Qiming Venture Partners, will take place on October 15, 2026, in Hangzhou, Zhejiang. As a premier entrepreneurship competition in biotech, the call for proposals (via the S2SChina website) from China's top universities and research institutions has entered its final countdown (deadline: March 1, 2026).
S2S (Science2Startup) is a globally renowned life sciences startup incubation platform founded in 2018 by F-Prime Capital, SV Health, and Atlas Venture. It has since evolved into a central engine for global biotech innovation. S2S China is jointly launched by RA Capital Management and Qiming Venture Partners. RA Capital Management is among the most active asset management firms in global life sciences and healthcare. Qiming Venture Partners is known for its forward-looking, industry-leading investments in healthcare innovation, consistently ranking within the global top five. Through this powerful partnership, the two firms aim to accelerate the commercialization and globalization of China's biopharmaceutical technologies via the S2S platform.
The S2S Symposium is a platform for selected scientists to showcase their research. This invitation-only event allows top scientists to present their entrepreneurial concepts and engage directly with leading biotech investors.
Following the successful incubation of over 14 startups and the 2024 S2S Japan Symposium, S2S is now turning its attention to China's scientific community. The inaugural S2S China Symposium aims to build a bridge connecting China's world-class research with top-tier global biopharma capital. It is dedicated to unlocking the life sciences potential of China's academic sector, providing a stage for early-stage research projects that have not yet raised Series A funding or even established a legal entity.
For this call for proposals, S2S China is seeking breakthrough technologies at the proof-of-concept stage. Ideal candidates should demonstrate:
— Novel proprietary academic technology in a therapeutic area
— A path to clinical application within 4-5 years, supported by key data
— Significant advantages over existing therapies (e.g., better addressing unmet clinical needs)
Unlike a typical pitch event, S2S employs a unique "mentorship model" that pairs selected scientists with VC mentors — the two sides work one-on-one to deeply refine entrepreneurial concepts and presentations across dimensions including novelty, therapeutic potential, and commercialization pathways. Selected scientists will have the opportunity to communicate directly with world-class investment firms and industry executives to explore potential investment opportunities. These leading institutions include RA Capital, Qiming Venture Partners, F-Prime, Atlas Venture, 5AM Ventures, Lilly Asia Ventures, and Hillhouse. Beyond potential investment, selected scientists will also have opportunities to build cross-border partnerships. Additionally, S2S China will provide travel funding for finalists to ensure their ideas can be presented without barriers.
This is a rare opportunity for direct access to a premier global investment network. We invite top scientists to visit the S2SChina website and submit proposals today, embarking on an accelerated journey from lab to startup. See you in Hangzhou on October 15, 2026!
Past Coverage
Qiming Honors | 5 Qiming Venture Partners Investors Named to 2025 Forbes China Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.